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Abstract
Background: Histone modifications and DNA methylation are two major factors in epigenetic phenomenon.
Unlike the histone deacetylase inhibitors, which are known to exert radiosensitizing effects, there have only been a
few studies thus far concerning the role of DNA methyltransferase (DNMT) inhibitors as radiosensitizers. The
principal objective of this study was to evaluate the effects of DNMT inhibitors on the radiosensitivity of human
cancer cell lines, and to elucidate the mechanisms relevant to that process.
Methods: A549 (lung cancer) and U373MG (glioblastoma) cells were exposed to radiation with or without six
DNMT inhibitors (5-azacytidine, 5-aza-2’-deoxycytidine, zebularine, hydralazine, epigallocatechin gallate, and
psammaplin A) for 18 hours prior to radiation, after which cell survival was evaluated via clonogenic assays. Cell
cycle and apoptosis were analyzed via flow cytometry. Expressions of DNMT1, 3A/3B, and cleaved caspase-3 were
detected via Western blotting. Expression of gH2AX, a marker of radiation-induced DNA double-strand break, was
examined by immunocytochemistry.
Results: Pretreatment with psammaplin A, 5-aza-2’-deoxycytidine, and zebularine radiosensitized both A549 and
U373MG cells. Pretreatment with psammaplin A increased the sub-G1 fraction of A549 cells, as compared to cells
exposed to radiation alone. Prolongation of gH2AX expression was observed in the cells treated with DNMT
inhibitors prior to radiation as compared with those treated by radiation alone.
Conclusions: Psammaplin A, 5-aza-2’-deoxycytidine, and zebularine induce radiosensitivity in both A549 and
U373MG cell lines, and suggest that this effect might be associated with the inhibition of DNA repair.
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Background
Epigenetic alteration is one of the most important gene
regulatory mechanisms. Unlike genetic alterations, epi-
genetic events are not changes in gene function that
occur in conjunction with DNA sequence changes.
Recently, epigenetic studies have been conducted in
many different aspects of biology, and particularly in the
cancer field. DNA methylation and histone modifica-
tions are two principal factors in epigenetic phenomena.
These two mechanisms perform a crucial function in
carcinogenesis and tumor progression.
DNA methylation is controlled by DNA methyltrans-
ferase (DNMT), an enzyme that catalyzes the transfer of
a methyl moiety from S-adenosyl-l-methionine to the 5-
postion of cytosines in the CpG dinucleotide [1].
DNMT overexpression has been detected in a variety of
malignancies, including lung, prostate, and colorectal
tumors [2-4].
Because DNA methylation is a reversible biochemical
process, DNMT may be a viable target for the treatment
of cancer. Since two cytidine analogues, 5-azacytidine
and 5-aza-2’deoxycytidine, have been reported in the
1980s, several DNMT inhibitors are currently under
investigation for their possible utility in treating a variety
of tumors [5-7].
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and DNA methylation are intricately interrelated in terms
of affecting chromatin structure and gene expression [8].
Because these two parameters have long been implicated
in the regulation of cellular radioresponse, histone deace-
tylase (HDAC) inhibitors and DNMT inhibitors might be
considered potential targets for radiosensitization. Actu-
ally, several studies have reported that HDAC inhibitors
such as trichostatin A induce radiosensitization [9-11].
However, relatively little information is currently available
concerning the use of DNMT inhibitors in this context
[12,13]. This allows us to evaluate the functions of DNMT
inhibitors as radiosensitizing agents.
We tried to assess the influence of a variety of DNMT
inhibitors on radiosensitivity in two human cancer cell
lines of different histologic origins, and to elucidate the
mechanisms relevant to those influences.
Methods
Cell culture and DNMT inhibitors
In this study, two different cancer cell lines were chosen:
A549, a human lung cancer cell line harboring wild-type
p53, and U373MG, a human glioblastoma cell line harbor-
ing inactive mutant p53. The A549 and U373MG cell lines
were purchased from the Korean Cell Line Bank. Cells
were cultured at 37°C in water saturated with 5% CO2.
The cultures were maintained in RPMI media (Welgene,
Daegu, Korea), supplemented with 10% fetal bovine serum
and 12.5 μg/ml of gentamicin.
5-azacytidine, 5-aza-2’-deoxycytidine, zebularine, hydra-
lazine, epigallocatechin gallate (EGCG), and psammaplin
A were obtained from Sigma Chemical Co. (St. Louis,
MO, USA), and dissolved as concentrated stock solutions
in DMSO, stored at -20°C, and diluted in the respective
culture media at the time of use. Control cells were treated
with media containing an equal concentration of the drug
carrier, DMSO.
Clonogenic assay
Cells were trypsinized from the exponentially growing
monolayer cultures. The appropriate numbers of cells
were seeded into T25 flasks, and then incubated for
24 hours prior to treatment. To compare the combined
cytotoxic effect of DNMT inhibitors and radiation with
that of radiation alone, radiation was administered with 6
MV of x-rays from a linear accelerator (Clinac 2100 C or
Clinac 21EX, Varian Medical systems, Palo Alto, CA,
USA) with graded doses of x-rays. In combined treat-
ment, DNMT inhibitors (5-azacytidine, 5-aza-2’-deoxycy-
tidine, zebularine, hydralazine, EGCG and psammaplin
A) were administered for 18 hours prior to radiation.
O u rp r e v i o u ss t u d i e sf o re p i g e n t i c s ,i nw h i c hH D A C
inhibitors had been used, showed that the greatest degree
of radiosensitization was observed when cells are
pretreated with epigenetic drugs before irradiation for 18
hours. Based on these results, all subsequent experiments
were done with DNMT inhibitors added before radiation
for 18 hours [10]. To cancel out additive cytotoxicity of
DNMT inhibitor and reveal synergism with radiation, we
normalized surviving fractions of irradiated cells by using
corresponding plating efficacies of unirradiated cells
within respective groups. The cells were incubated for 14
to 21 days to allow for the formation of colonies. The
colonies formed were fixed with methanol and stained
with 0.5% crystal violet; the number of colonies contain-
ing at least 50 cells was determined, and the surviving
fraction (SF) was then calculated. Each point on the sur-
vival curves represents the mean surviving fraction from
at least three dishes.
Flow cytometric analysis
The effects of DNMT inhibitors on cell cycles were ana-
lyzed via flow cytometry. All centrifugation procedures
were conducted for 4 min at 1500 rpm. The cells were
treated with RPMI or an IC50s concentration of DNMT
inhibitors for 18 hours. The cells were sham-irradiated or
irradiated with 6 Gy of 6 MV x-ray and were collected at
0, 2, 6, 12 and 24 hours after radiation. The cells were har-
vested at the indicated times and fixed in 2 mL of 80%
ethanol for 24 hours for fixation. The fixed cells were then
washed twice in PBS, and suspended in PBS on ice for
5 min. After centrifugation, the cell pellets were washed
and resuspended in 5 μg/ml propidium iodide (Molecular
Probes, Eugene, OR, USA) and 0.1% RNase A (Sigma). At
least 1 × 10
4 events were counted.
Western blot for DNMT1, DNMT3A/3B, and cleaved
caspase-3
Cell lysates were prepared in cell lysis buffer (iNtRON
Biotechnology, Seoul, Korea). The total cellular proteins
(50 μg) were separated on SDS-PAGE and transferred to
nitrocellulose membranes (Millipore Corp., Bedford, MA,
USA). The membranes were blocked with blocking solu-
tion in 5% nonfat dry milk (25 mM Tris, pH 7.5; 0.15 M
NaCl; 0.05% Tween) for 1 hour and probed with primary
rabbit polyclonal IgG antibody at a dilution of 1:1,000
overnight. The antibody for DNMT1 was obtained from
A b c a m( C a m b r i d g e ,U K ) ,a n dD N M T 3 A ,D N M T 3 Ba n d
cleaved caspase-3 antibody were purchased from Cell
Signaling Technology (Beverly, MA, USA). The mem-
branes were incubated with blocking solution containing
a dilution of HRP-conjugated goat anti-rabbit IgG as a
secondary antibody (Santa Cruz, Biotechnology, CA,
USA) at 1:2,000 for 2 hours. Western blot protein detec-
tion was conducted using the ECL kit (Intron Biotechnol-
ogy, Seongnam, Korea) according to the manufacturers’
recommendations. As a control, monoclonal antibody
against actin (Santa Cruz) was utilized.
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Cells were grown and treated in tissue culture chamber
slides (Nalge Nunc International, Naperville, IL, USA).
At the specified times, the medium was aspirated and
the cells were fixed in 4% paraformaldehyde for 10 min-
utes at room temperature. The paraformaldehyde was
aspirated, and the cells were treated for 15 min with a
0.2% NP40/PBS solution. The cells were then washed
twice in PBS, and anti-gH2AX antibody (Cell Signaling
Technology) was added at a dilution of 1:200 in 1%
bovine serum albumin and incubated overnight at 4°C.
The cells were again washed twice in PBS prior to
1 hour of incubation in the dark with an FITC-labeled
secondary antibody (Invitrogen, Camarillo, CA, USA) at
a dilution of 1:50 in 1% bovine serum albumin. The sec-
ondary antibody solution was then aspirated and the
cells were washed twice in PBS, followed by 30 minutes
of incubation in the dark with 4’,6diamindino-2-pheny-
lindole (1 μg/mL) in PBS and two subsequent washings.
The coverslips were then mounted with antifade solu-
tion (Vector Laboratories, Burlingame, CA, USA). Slides
were examined with a Leica DMRXA fluorescent micro-
scope (Leica, Wetzlar, Germany). The images were cap-
tured using a Photometrics Sensys CCD camera (Leica)
and imported into the IP Labs image analysis software
package (Leica). For each treatment condition, the num-
bers of gH2AX foci were counted in 50 cells. Cells were
classified positive (i.e., containing radiation-induced
gH2AX foci) when more than five foci were detected
[14].
Statistics
Kaleidagraph version 3.51 (Synergy Software, Reading,
PA, USA) was utilized to fit the survival data of irra-
diated cells into a linear quadratic (LQ) model and to
estimate the a and b values. The LQ model was defined
as follows:
SF = e - (αd+ βd2)
Differences in mean values between groups were com-
pared using Student t-test. Probability values of p < 0.05
were regarded as statistically significant.
Results
Cytotoxic effect and determination of IC50s of DNMT
inhibitors
Increasing concentrations of six DNMT inhibitors
reduced the viability of two cell lines. The 50% inhibi-
tory concentrations (IC50s) were determined after an 18-
hour exposure to six DNMT inhibitors, and those con-
centration were used in subsequent experiments. The
IC50so fD N M Ti n h i b i t o r sa r es h o w ni nT a b l e1 .I C 50
value of zebularine in A549 cells could not be obtained
because no significant inhibition of cell growth was
observed at any dose. Thus, IC50 value in U373MG, 800
uM, was used in subsequent experiments in A549 cells.
Effects of DNMT inhibitors on radiosensitivity of A549
and U373MG cell lines
Survival curves of A549 and U373MG cells treated with
DNMT inhibitors and radiation were compared with
those of cells treated with radiation alone. Among six
DNMT inhibitors, psammaplin A, 5-aza-2’-deoxycyti-
dine, and zebularine pretreatment significantly enhanced
radiation cell killing in both A549 and U373MG cells
lines (Figure 1A and 1B). Using the dose required to
generate a SF of 0.5 as a reference, the dose enhance-
ment ratios (DER) were estimated. The DERs of psam-
maplin A, 5-aza-2’-deoxycytidine, and zebularine for the
A549 cell line were 1.29, 1.96, and 1.69, respectively and
for U373MG were 1.29, 1.55, and 2.13, respectively.
Effects of DNMT inhibitors on DNMT expression
DNMT1, DNMT3A, and DNMT3B are the three main
functional methyltransferases responsible for the estab-
lishment and maintenance of DNA methylation patterns
in mammals. The effects of DNMT inhibitors on the
levels of DNMT expression were analyzed via Western
blotting using specific antibodies against DNMT1,
DNMT3A, and DNMT3B. Western blot analysis
revealed a drastic depletion of DNMT1 and DNMT3A
by psammaplin A, 5-aza-2’-deoxycytidine, and zebular-
ine in both A549 and U373MG cell lines. However, no
depletion of DNMT3B by the three DNMT inhibitors
was observed in either of the cell lines (Figure 2). These
results indicate that DNMT inhibitors induce selective
demethylation in each of the evaluated tumor cell lines.
Mechanisms of radiosensitization
Cell cycle and apoptosis were evaluated by flow cytome-
try. Both cell lines evidenced a G2/M delay after radia-
tion treatment alone. Although the effects of combining
DNMT inhibitors and radiation vary between cell lines,
we noted no significant differences in cell cycle phase
Table 1 IC50 values for six DNMT inhibitors
Drugs Cell lines
A549 U373MG
5-azacytine 3 uM 3 uM
5-aza-2’-deoxycytidine 300 nM 100 nM
Zebularine 800 uM ND*
Hydralazine 2 uM 20 uM
Epigallocatechin gallate 15 uM 5 uM
Psammaplin A 5 ug/ml 5 ug/ml
*ND; not determined, IC50 value in U373MG, 800 uM, was used in subsequent
experiments in A549 cells
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alone and those treated with a combination of radiation
combined with DNMT inhibitors (Figure 3). However,
in the A549 cells, radiation-induced G2/M arrest was
abrogated by zebularine pretreatment at 6-12 hours, but
this abrogation disappeared at 24 hours (Figure 3 and
4).
Psammaplin A pretreatment increased the sub-G1
fraction of A549 cells, as compared to cells exposed to
radiation alone (Table 2). Western blotting also revealed
an increased expression of cleaved caspase-3 in psam-
maplin A pretreated A549 cells (Figure 5). However,
psammaplin A exerted no effect on the apoptotic induc-
tion of U373MG cell lines. Pretreatment with other
DNMT inhibitors did not influence the expression of
cleaved caspase-3 in either of the cell lines.
gH2AX has been identified as a marker of DNA dou-
ble-strand break (DSB) [15]. Immunocytochemical ana-
lysis using the anti-gH2AX antibodies was conducted in
order to determine the effects of DNMT inhibitors on
DNA repair. As shown in the representative micro-
graphs in Figure 6, gH2AX foci could be clearly
distinguished after the 6 Gy of radiation. The gH2AX
expression of cells treated with radiation alone was
compared with those treated with a combination of
DNMT inhibitors and radiation. Although gH2AX foci
expression was shown to be reduced in cells treated
with radiation alone over time, gH2AX foci levels in the
cells exposed to DNMT inhibitors prior to radiation
remained constant over a 12-hour time course in A549
cells and over a 24-hour time course in U373MG cells
(Figure 7). These results implicate an inhibition of the
DNA damage repair process as the possible mechanism
underlying the effects of DNMT inhibitors on
radiosensitization.
Discussion
Recently, histone modifications and DNA methylation,
both of which are prominent epigenetic mechanisms,
have been evaluated with a view toward enhancing the
radiosensitivity of tumor cells via the regulation of chro-
matin structure modifications and the expression of
genes involved in cell cycle checkpoints, apoptosis, and
DNA repair. A number of investigators have previously
reported that several HDAC inhibitors exert direct cyto-
toxic effects, and can sensitize tumor cells to radiother-
apy [14,16-19]. Kim et al. also demonstrated that
trichostatin A, which is the most potent HDAC inhibi-
tor identified thus far, enhanced radiosensitivity in a
Figure 1 The effects of DNMT inhibitors on tumor cell
radiosensitivity. Survival curves of (A) A549 cells and (B) U373MG
cells treated with the respective DNMT inhibitors prior to radiation
and radiation were compared with those of radiation alone. Points,
mean for three independent experiments; bars, SE.
Figure 2 Methylation status was determined after exposure to
DNMT inhibitors using Western blot analysis of DNMT1, 3A/3B.
The cells were treated with DNMT inhibitors for 18 hours. A drastic
depletion of DNMT1 and DNMT3A by psammaplin A, 5-aza-
2’deoxycytidine, and zebularine in both A549 and U373MG cell lines
was observed. However, there was no depletion of DNMT3B by the
three DNMT inhibitors in either of the cell lines. Each blot is
representative of two independent experiments, with actin used as
a loading control.
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HDAC inhibitors, however, little information is cur-
rently available regarding the effects of DNMT inhibi-
tors on radiosensitization [12,13].
There are two classes of DNMT inhibitors: the nucleo-
side analogues and the non-nucleoside analogues. Several
compounds are currently being evaluated in preclinical
and clinical trials for the treatment of solid and hemato-
logical malignancies. Contrary to their effect in hemato-
logic malignancies, the clinical effects of these
compounds against solid tumors have yet to be evaluated
[21]. Therefore, the use of epigenetic therapies in combi-
nation with other regimens, such as conventional che-
motherapeutics or radiotherapy, should be considered.
As DNA methylation is intricately interrelated with chro-
matin structure and gene expression, parameters long
thought to be involved in the regulation of cellular
radioresponse, it is critically important to evaluate the
effects of DNMT inhibitors on radiosensitization. In
order to assess this possibility, we employed a total of six
DNMT inhibitors. Among them, 5-aza2’-deoxycytidine,
zebularine, and psammaplin A were shown to exert a
radiosensitizing effect in both A549 and U373MG cells.
Although some differences in the degrees of radiosensiti-
zation were detected according to the different DNMT
inhibitors and cell lines used, these results demonstrate
that some DNMT inhibitors may prove to be useful
radiation sensitizers in human cancer cells.
5-aza-2’-deoxycytidine, along with 5-azacytidine, is the
first DNMT inhibitor reported, and evidences clinical
efficacy in cases of myelodysplastic syndrome and acute
myelogenous leukemia. Several previous studies have
demonstrated that 5-aza-2’-deoxycytidine exerts a radio-
sensitizing effect, with or without HDAC inhibitors, in a
variety of cancer cell lines [13,22,23]. Recently, the radio-
sensitization effect of 5-azacytidine was also referenced
by Hofstetter et al., who demonstrated that 5-azacyti-
dine-induced genomic hypomethylation induces
enhanced radiation sensitivity in colorectal carcinoma
[24]. These results are logical consequences, considering
that 5-azacytidine has a molecular structure and exerts
clinical effects similar to those of 5-aza-2’-deoxycytidine.
However, in this study, 5-azacytidine did not sensitize
either of the tested cancer cell types to radiotherapy. 5-
azacytidine may exert differing effects on radiosensitivity
according to cell type, and the IC50 of 5-azacytidine var-
ies among different cell lines. Although this may explain,
at least in part, the different results detected in our study,
we did not successfully generate a definitive explanation
for the absence of any detectable radiosensitizing effect
of 5-azacytidine. Because very few studies have addressed
the role of 5-azacytidine as a radiosensitizer, further stu-
dies will be required to resolve this issue.
Zebularine, another 5-azacytidine derivative, was also
shown in this study to induce radiosensitivity. Zebularine
has been demonstrated to have anticancer properties,
Figure 3 Influence of DNMT inhibitors on cell cycle phase distributions of A549 and U373MG cells. Cell cycle phase was measured using
flow cytometry at 12 hours after 6 Gy of radiation. Columns, proportion of cell cycle phase; bars, SE.
Figure 4 The effect of zebularine on radiation-induced G2/M
arrest in A549 cells. A549 cells were treated with 800 uM
zebularine for 18 hours and then irradiated with 6 Gy. A549 cells
were accumulated in G2/M phase after radiation. This radiation-
induced G2/M arrest was abrogated by zebularine pretreatment at
6-12 hours, but this abrogation disappeared at 24 hours.
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silenced tumor suppressor p16 in solid malignancies.
However, its clinical development is limited by its higher
dosage and poor bioavailability, as observed previously in
rats, mice, and monkeys [6,25,26]. Owing to the relatively
h i g ht o x i c i t yo ft h e s en u c l e o s i d ea n a l o g u ec o m p o u n d s ,
non-nucleoside DNMT inhibitors are currently being
investigated for their possible use as anticancer agents.
The natural marine product, psammaplin A, was initi-
ally isolated from the Psammaplysilla sponge in 1987.
Since that time, psammaplin A has been shown to exert
potent cytotoxicity against several cancer cell lines, via
the selective induction of genes associated with cell
cycle arrest and apoptosis [27,28]. Because psammaplin
A has already been shown to exhibit potent histone dea-
cetylase inhibitory activity, this drug is a promising
radiosensitizing agent [28]. This is the first study in
which the radiosensitizing effects of psammaplin A have
been confirmed. As psammaplin A has not yet been the
subject of clinical trials, further clinical research should
be conducted to determine its efficacy when adminis-
tered in combination with radiotherapy.
Three different DNMTs exist, all of which are viable tar-
gets for DNMT inhibitors. DNMT1, the most abundant of
the three, is responsible for methylation during DNA
replication (maintenance methyltransferase). Other known
methyltransferases include DNMT3A and DNMT3B,
which exhibit identical preferences for hemi-methylated
Table 2 Apoptotic rates measured by the sub-G1 portion of flow cytometry in A549 and U373MG cells
Control/drug 0 h 2 h 6 h 12 h 24 h
A549 IR 1.11 ± 0.93 1.55 ± 0.82 3.01 ± 1.93 1.72 ± 0.83 1.20 ± 0.99 1.03 ± 0.33
PSA + IR 2.61 ± 1.05 1.53 ± 0.73 3.29 ± 1.71 8.02 ± 2.49 9.02 ± 3.20 7.72 ± 2.16
IR 0.53 ± 0.10 1.23 ± 1.07 0.98 ± 0.37 0.70 ± 0.06 1.13 ± 0.88 0.89 ± 0.12
DAC + IR 0.43 ± 0.10 1.20 ± 0.70 0.54 ± 0.02 0.57 ± 0.09 0.53 ± 0.07 1.05 ± 0.14
IR 0.59 ± 0.16 0.94 ± 0.60 0.61 ± 0.15 0.86 ± 0.33 1.77 ± 0.66 1.66 ± 0.14
ZEB + IR 0.84 ± 0.32 1.00 ± 0.61 0.97 ± 0.49 1.65 ± 0.52 1.62 ± 0.14 2.13 ± 0.05
U373MG IR 0.95 ± 0.10 0.61 ± 0.23 0.80 ± 0.18 0.71 ± 0.09 1.39 ± 0.20 1.68 ± 0.55
PSA + IR 0.71 ± 0.19 0.67 ± 0.13 0.55 ± 0.06 0.63 ± 0.05 0.89 ± 0.16 1.57 ± 0.61
IR 0.94 ± 0.05 0.64 ± 0.13 0.61 ± 0.05 0.64 ± 0.05 0.99 ± 0.20 1.68 ± 0.65
DAC + IR 0.77 ± 0.04 0.83 ± 0.01 0.58 ± 0.05 0.81 ± 0.08 0.93 ± 0.12 1.45 ± 0.37
IR 1.58 ± 0.25 1.39 ± 0.34 1.35 ± 0.01 1.12 ± 0.21 1.78 ± 0.34 2.33 ± 0.35
ZEB + IR 0.95 ± 0.19 1.90 ± 1.21 2.14 ± 1.48 1.06 ± 0.01 1.28 ± 0.15 4.59 ± 1.23
Abbreviations: IR = irradiation, PSA = psammplin A, DAC = 5-aza-2’-deoxycytidine, ZEB = zebularine
Figure 5 Western blot analysis of cleaved caspase-3.T h ec e l l s
were treated with a combination of three different DNMT inhibitors
and 6 Gy of radiation. Increased cleaved caspase-3 protein level was
observed in cells treated with a combination of psammaplin A and
6 Gy of radiation in the A549 cells.
Figure 6 Radiation-induced gH2AX foci.R e p r e s e n t a t i v e
micrographs obtained from (A) control cells and (B) cells that had
received 6 Gy of radiation 1 hour earlier. (A) top panel, (B) bottom
panel.
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as de novo methyltransferases. However, it has been
demonstrated that DNMT1 and DNMT3A/3B do not
appear to be completely distinct in their activities [29].
This supposition is based on two lines of evidence: first,
despite being DNMT1-deficient, a colon adenocarcinoma
cell line was shown to be capable of retaining 80% of its
methylation level while replicating, which implies that
DNMT3 may perform a function in the maintenance of
methylation [30]; secondly, forced DNMT1 overexpression
in cancer cell lines does, indeed, induce de novo methyla-
tion [31]. Gene silencing of DNMT, which functions as an
oncogene, has been proposed as a good cancer treatment
strategy [32]. In this study, three different DNMT inhibi-
tors, all of which demonstrated radiosensitizing effects,
depleted DNMT1 and DNMT3A, but no such DNMT3B
depletion was noted in the A549 and U373MG cell lines.
Depletion of DNMT, along with several members of the
structural maintenance of chromatin proteins (SMCs),
SMC-associated protein, and heterochromatin proteins,
was reported to correlate with chromatin decondensation
[33]. Considering that the effect of chromatin compaction
on protection of DNA against radiation-induced DSBs has
been relatively well-established [34,35], the relaxation of
chromatin structure via the downregulation of DNMT
with DNMT inhibitors may be a possible mechanism for
radiosensitization.
Selective inhibition of DNMT isoforms shown in this
study may be attributable, in part, to the doses of DNMT
inhibitors. Beaulieu et al. previously reported that Wes-
tern blot analysis with anti-DNMT1, DNMT3A, or
DNMT3B antibodies treated with increasing doses of
DNMT inhibitors effected a selective dose-dependent
inhibition of the target isoform of DNMT [36]. However,
as only the IC50 values of the DNMT inhibitors were
employed in this study, we were unable to ascertain
whether this selective inhibition of DNMT isoforms was
a function of the concentration of the drug.
In addition to the physical modification of chromatin
structure, cellular processes that can affect intrinsic
radiosensitivity were evaluated in this study. Cell cycle,
apoptosis, and DNA repair have all been shown to influ-
ence radiosensitivity.
The proportion of cells in the G2/M phase detected in
this study was not significantly altered by pretreatment
with DNMT inhibitors, and no abrogation of radiation-
induced G2/M arrest was noted except in the zebularine-
treated A549 cell line. Radiation-induced G2/M arrest was
abrogated as the result of zebularine pretreatment at 6-12
hours, but this effect disappeared at 24 hours in the A549
cell line. In another study, zebularine was not found to
result in the abrogation of radiation-induced G2/M arrest
in a U251 glioblastoma cell line [12]. Thus, although there
appears to be some relationship between cell lines and
radiation-induced G2/M arrest, it is less likely that the
radiosensitization induced by the DNMT inhibitors
employed in this study is the result of a general inhibition
of G2 checkpoint activation.
Apoptosis has previously been regarded as a potential
mechanism for radiosensitization. Different results have
been reported regarding the role of apoptosis as a radio-
sensitizing mechanism induced by DNMT inhibitors.
Dote et al. previously reported that a combination of
radiation and zebularine did not significantly increase
the sub-G1 population (apoptotic cells) [12]. On the
other hand, Qui et al. demonstrated that 5-aza-2’-deoxy-
cytidine induces radiosensitization in certain gastric can-
cer cell lines via induced increases in the apoptotic rate,
as evidenced by enhanced expression of the p53,
RASSF1, and DAPK gene families [23]. In this study, the
Figure 7 Influence of DNMT inhibitors on radiation-induced gH2AX foci. A549 and U373MG cells growing in chamber slides were exposed
to DNMT inhibitors for 18 hours, irradiated, and fixed at specific times for immunocytochemical analyses of nuclear gH2AX foci. Open columns,
data from cells receiving radiation alone; grey columns, data from cells that were exposed to psammaplin A and radiation; filled columns, data
from cells that were exposed to 5-aza-2’-deoxycytidine and radiation; hatched columns, data from cells that were exposed to zebularine and
radiation. Cells with more than five foci per nucleus were classified as positive for radiation-induced gH2AX. Foci were evaluated in 50 nuclei.
Bars, SE. *p < 0.01 as determined by a logistic regression compared with radiation alone (6 Gy) group.
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radiation did not increase the apoptosis rate in either of
the cell lines. However, exposure to psammaplin A in
the A549 cell line induced a significant increase in
apoptotic death. Psammaplin A has been reported to
exert cytotoxic effects on cancer cells via the selective
induction of apoptosis-related genes [27]. This effect of
psammalin A may result in an increase in radiation-
induced apoptosis. However, in this study, radiation-
induced apoptosis was noted only in the A549 cell line,
and not in the U373MG cell line. This finding may be
attributable, at least in part, to p53 expression status.
The U373MG cell line, which contains mutated p53,
might be comparatively resistant to radiation-induced
apoptosis, considering that apoptosis is mediated by the
p53 protein.
DNA repair is another process involved in the deter-
mination of cellular radiosensitivity. The activation of
DNA repair of cancer cells after sublethal DNA damage
induced by radiation might be one of the most impor-
tant factors in resistance. The expression of gH2AX has
been recently identified as a sensitive indicator of radia-
tion-induced DSBs [37]. In this study, gH2AX expres-
sion in cells treated with a combination of DNMT
inhibitors (5-aza-2’deoxycytidine and psammaplin A, as
well as zebularine) was found to be similar to the results
achieved with radiation treatment at 1 hour after initial
treatment, but was significantly greater over time. This
finding is generally consistent with the results obtained
in other previous studies, in which zebularine and 5-
aza-2’-deoxycytidine were employed as radiosensitizing
agents [12,22]. Dote et al. evaluated the expression of
gH2AX foci after exposure to 2 Gy with and without
zebularine pretreatment. Whereas zebularine had no
effect on radiation-induced gH2AX foci at 1 hour, the
number of gH2AX per cell was significantly greater in
the zebularine-treated cells at 24 hours after irradiation,
which suggested the possible presence of unrepaired
DNA damage [12]. DNA methylation is intimately asso-
ciated with histone deacetylases in terms of the epige-
netic regulation of gene expression. Actually, HDAC
inhibitors such as LBH589 and MS-275 have been
shown to enhance radiosensitivity through similar
mechanisms as those of the DNMT inhibitors. These
HDAC inhibitors prolonged gH2AX expression, suggest-
ing an inhibition of DNA repair [14,38]. A previous pre-
clinical study demonstrated that an HDAC inhibitor
downmodulated the expression of DNA-PK and Rad51,
which participated in the recovery of DSB, thereby abro-
gating key cellular pathways involved in DNA DSB
repair [17]. These results indicate that the impairment
o fD N AD S Br e p a i rm a yb eo n eo ft h em o s tc r u c i a l
mechanisms underlying enhanced radiation responses in
epigenetic phenomena. Based on this assumption,
further investigations are warranted to determine
whether or not alterations in the methylation patterns
of a specific gene or set of genes involved in DNA repair
might be modulated by DNMT inhibitors, and that
these changes might contribute to the observed
enhancements of radiosensitivity.
Several remain to be determined in future studies.
First, a unified treatment schedule - specifically, the
administration of DNMT inhibitors 18 hours prior to
radiation - was employed in this study, and thus the
optimal treatment schedule of DNMT inhibitors and
radiation remains to be established. In other studies,
DNMT inhibitors were administered for different treat-
ment durations, i.e. 2 ~ 48 hours prior to radiation, con-
sidering several factors such as drug half-lives and the
expression of radiosensitivity-related genes [22,23].
Further investigations into the optimal treatment sche-
dule of DNMT inhibitors and radiation for clinical
applications will be necessary in the future.
Second, another important issue will involve assess-
ments of the synergistic effects of DNMT inhibitors and
HDAC inhibitors on radiosensitivity. Although some
previous studies have reported that the combined gene
silencing reversal effect was superior to that of treat-
ment with a single agent [32,39], only a few studies have
thus far evaluated the influence of this combined effect
on increased radiosensitivity. Third, the mechanisms
underlying DNMT inhibitor-induced radiosensitzations
need further investigation. We speculate that suppres-
sion of DNMTs by the DNMT inhibitors was associated
with enhanced radiosensitivity through the change in
DNA structure. However, the relationship between
DNA methylation and cellular radiosensitivity is to be
elucidated in the future study.
Conclusions
Taken together, our study indicate that psammaplin A,
5-aza-2’-deoxycytidine, and zebularine have the potential
to increase radiosensitivity in lung cancer A549 and
glioblastoma U373MG cells, most probably by modulat-
ing the impairment of the DNA repair process. Further
investigations will be required to identify other addi-
tional mechanisms associated with radiosensitivity, and
to confirm the synergistic effects on radiosensitivity with
other epigenetic drugs, such as the HDAC inhibitors.
Also, future studies should be conducted to determine
definitively whether the combination of DNMT inhibi-
tors and radiation has real potential as a clinical strategy
for the treatment of cancer.
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